作者： sarah

TOKYO, Nov 5, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai Innovation,Inc. has been selected as a registered venture capital (Registered VC) of the Strengthening Program for Pharmaceutical Startup Ecosystem implemented by the Japan Agency for Medical Research and Development (AMED).To address the shortage of large-scale funding necessary for new drug development, this program provides subsidies to pharmaceutical startups for development and commercialization. This support is contingent upon startups securing funding from AMED-registered venture capital firms, which specialize in drug development and offer hands-on business management and commercialization support.The Eisai global network of affiliated companies (the “Eisai Group”) launched its venture investment business in May 2019, aiming to support the acceleration of drug discovery innovation and the establishment of an ecosystem platform in areas includingdementia. This involves supporting the discovery of innovative technologies and services by supporting venture businesses with such capabilities and exploring possible future collaborations with these businesses. Eisai Innovation, Inc. was established in theU.S. in August 2019 as Eisai’s corporate venture capital subsidiary. It identifies opportunities for the Eisai Group to invest in venture businesses that align with Eisai’s goal of contributing to patients, focusing on cutting-edge drug discovery platforms, andnew modalities, as well as leading biotechnology in focus areas of neurology, oncology, and global health. The company also supports investment in drug discovery technologies in other areas, where significant future innovations are anticipated. As anAMED-registered VC, Eisai Innovation, Inc. aims to further contribute to strengthening the drug discovery venture ecosystem in Japan.Eisai and Eisai Innovation, Inc. are committed to utilizing their participation in the Strengthening Program for PharmaceuticalStartup Ecosystem to accelerate flexible support of academia, drug discovery ventures, and IT ventures, to create innovative new medicines targeting diseases with high unmet medical needs., Eisai aims to effectively achieve social good in the form of relievinganxiety over health and reducing health disparities by creating solutions through an ecosystem in collaboration with other industries.*Please refer to following web page for Eisai’s venture investment businesswww.eisai.com/innovation/cvc/index.html https://www.eisaiinnovation.com/MEDIA CONTACTSEisai Co., Ltd.Public Relations Department TEL : +81 (0)3-3817-5120Eisai Innovation, Inc. https://www.eisaiinnovation.com/ Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Nov 4, 2024 - (JCN Newswire via SeaPRwire.com) - Asahi Kasei Corporation (Asahi Kasei) and Honda Motor Co., Ltd. (Honda) announced today that the two companies have signed a shareholders’ agreement to convert an existing Asahi Kasei subsidiary in Canada into a joint venture company. This agreement was reached as a result of continued discussions on collaboration for the production of lithium-ion battery separators in Canada based on the basic agreement the two companies announced on April 25, 2024.Configuration for separator production in North AmericaThe two companies plan to convert E-Materials Canada Corporation (E-Materials), a wholly owned subsidiary of an Asahi Kasei subsidiary in Canada, into a joint venture between Asahi Kasei and Honda to be renamed Asahi Kasei Honda Battery Separator Corporation (tentative name). This will be based on Honda Canada Inc., a Honda subsidiary in Canada, acquiring a 25% stake by subscribing to new shares to be issued by E-Materials through a third-party allotment. Honda will invest a total of approximately C$417 million (approximately US$300 million) combining the subscription of new shares and other investment in this joint venture. The two companies will combine each other’s strengths, such as high value-added material technologies and electrification technologies, to produce high-quality separators to be utilized for lithium-ion batteries that will accelerate the realization of high-performance electrified vehicles.The two companies plan to establish and start the operation of the joint venture company in early 2025, subject to obtaining permits and approvals from relevant authorities.Comments by Ryu Taniguchi, President & Representative Director, Asahi Kasei Battery Separator Corp.“At the beginning of October we launched Asahi Kasei Battery Separator as a new company for the Hipore™ separator business to achieve more nimble management for this essential component of lithium-ion batteries. I am confident that we can continue to leverage the technology and experience gained with Hipore™ as well as our global network and diverse personnel to realize innovations in batteries for the future of energy storage. As Honda strives toward the goal of carbon neutrality by 2050, it is building a comprehensive electric vehicle value chain in Canada, where it has a history of conducting business for more than 50 years. Our partnership will not only establish stable supply of separators in North America, together we will enhance battery performance and durability to advance the energy transition through electric vehicles, making an important contribution to sustainability.”About the joint venture company (tentative)- Company name:Asahi Kasei Honda Battery Separator Corporation (tentative)- Location:Port Colborne, Ontario, Canada- Capital:Approximately C$240 million- Investment ratio:75% Asahi Kasei Battery Separator Canada Corporation25% Honda Canada Inc.Outline of the investment by the joint venture company (tentative)Plant overview:Integrated plant for the base film manufacturing and coating of Hipore™ lithium-ion battery separatorTotal investment amount:180 billion yen(with assumed exchange rate of 1 USD=145 yen)Production capacity:Approximately 700 million m2 per year (as coated film)Start of operationsCommercial start-up scheduled in 2027About HondaSince its foundation, Honda has been committed to "creating a society that is useful to people" by utilizing its technologies and ideas. We also focus on environmental responsiveness and traffic safety, and continue to take on the challenge of realizing a sustainable future. For more information, visit https://global.honda/en/.Head Office Contact Information: 2-1-1, Minami-Aoyama, Minato-ku, Tokyo 107-8556, JapanTel: +81-(0)3-3423-1111 (main) Copyright 2024 JCN Newswire via SeaPRwire.com.

Susono, JAPAN and Santa Cruz, California, Nov 4, 2024 - (JCN Newswire via SeaPRwire.com) - Toyota Motor Corporation (Toyota) and Joby Aviation (Joby) came together at Toyota's Higashi-Fuji Technical Center (Shizuoka, Japan) to assert their collective passion and ambition for air mobility in a gathering that included executives from both companies, Akio Toyoda, the chairman of the Toyota Group, and Joby CEO and founder, JoeBen Bevirt, along with Joby's air taxi, an electric vertical takeoff and landing aircraft (eVTOL*).Since its founding, Toyota has been working to realize a society in which everyone can move freely. About 100 years ago, in 1925, Sakichi Toyoda, founder of the Toyota Group, offered a prize to encourage the development of a storage battery that could provide enough performance "to fly an airplane across the Pacific Ocean." Since then, Toyota has continued to focus on the challenge of air mobility through the generations. Toyota Motor Corporation founder Kiichiro Toyoda also expressed a strong interest in the aircraft business, making prototypes of helicopters and aircraft components. After World War II, among other developments, Dr. Shoichiro Toyoda was involved in the joint development of the world's first electronically controlled aero piston engine with an American company at Toyota's Higashi Fuji Technical Center, which could be described as the birthplace of Toyota's development of air mobility. Today, Sakichi's dream carries on, with batteries seen as a viable source of power for eVTOL.As Toyota transforms into a mobility company, it has been able to work with other great companies like Joby to find new and exciting opportunities. Joby's CEO, JoeBen Bevirt, is driven by his passion and dreams that "look forward to a world where our environmental footprint is smaller, a world where we're able to spend more time with the people and places that matter most to us, without having to worry about traffic jams." Akio Toyoda, chairman of the Toyota Group, has ambitions to bring the freedom of mobility to all people. The two leaders met and began a journey together. The culmination of the efforts of both companies over the last seven years, in which Joby's dream and passion for air mobility as a startup met Toyota's expertise in production processes and technology development, led to Joby's first air taxi exhibition flight overseas in Japan.JoeBen Bevirt, Founder and CEO of Joby (left), Akio Toyoda, Chairman of Toyota Motor Corporation (right)"This is a moment we have been looking forward to for a long time and marks a significant milestone on our journey towards making clean air travel an everyday reality," said JoeBen Bevirt, Founder and CEO of Joby. "We share Toyota's vision for the future of air travel and are honored to have had the opportunity to present a glimpse of that future through our exhibition flight in Japan."Link to full speech script"Air mobility has the potential to change our `sense of distance and time,' and open a future with the new option of air mobility that will further enrich the lives of many people," said Hiroki Nakajima, member of the board and executive vice president of Toyota Motor Corporation. "Toyota is committed to deepening our collaboration with Joby and we will continue to work together to realize our shared dreams."Link to full speech scriptToyota is committed to building on its mobility businesses to deliver mobility for all, and to bring smiles to people's faces. Together, Toyota and Joby will work to realize a future that offers more freedom and prosperity to all.About electric Vertical Take Off and Landing (eVTOL)An eVTOL is a type of aircraft designed for short-range, high-frequency operations suitable for the on-demand air taxi market, which is expected to be utilized by commuters, business travelers, and tourists in urban areas. Combining elements from helicopters, drones, and small aircraft, eVTOLs aim to excel in reliability, environmental performance (zero operating emissions), quiet operation, operational and maintenance costs, enhanced safety features, and more.*Electric Vertical Take-Off and Landing eVTOLAbout Toyota Toyota strives to be a strong corporate citizen, engaging with and earning the trust of its stakeholders, and to contribute to the creation of a prosperous society through all its business operations.Our corporate principles form the basis of our initiatives, reflect values that enable action, and drive our mindset.For the latest Toyota-related news and information:https://tinyurl.com/ToyotaPressReleasenewsroom@global.toyota Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Nov 1, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd.  and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). If the FDA accepts the BLA, the Prescription Drug User Fee Act (PDUFA) action date (target date for completion of examination) will be set.The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If approved by the FDA, the LEQEMBI autoinjector could be used to administer LEQEMBI at home or at medical facilities, and the injection process is expected on average to take about 15 seconds. As part of the subcutaneous autoinjector 360 mg weekly maintenance regimen under review, patients who have completed the biweekly intravenous (IV) initiation phase would receive weekly doses that maintain effective drug concentrations to sustain the clearance of highly toxic protofibrils* which can continue to cause neuronal injury even after the amyloid-beta (Aβ) plaque has been cleared from the brain.AD is an ongoing neurotoxic process that begins before and continues after plaque deposition. Data suggest that early and continuing treatment may prolong the benefit of therapy even after plaque is cleared from the brain. This SC autoinjector is expected to be easier for patients and their care partners to use and may reduce the need for hospital or infusion site visits and nursing care compared to IV administration. In addition to potentially maintaining the clinical and biomarker benefits, subcutaneous maintenance dosing may be more convenient for patients and their care partners to continue the treatment.LEQEMBI is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE and Great Britain. Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union (EU). The US FDA accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly LEQEMBI IV maintenance dosing in June 2024 and set a PDUFA action date for January 25, 2025.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2INDICATIONLEQEMBI® [(lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.For the full press release, visit https://www.eisai.com/news/2024/news202482.html. About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S.,3 Japan,4 China,5 South Korea,6 Hong Kong,7 Israel,8 the United Arab Emirates9 and Great Britain.10 Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union (EU).LEQEMBI’s approvals in these countries was based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with lecanemab reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.11,12 The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001). In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the lecanemab group and −5.5 in the placebo group (difference, 2.0; 95% CI, 1.2 to 2.8; P<0.001). The ADCS MCI-ADL assesses the ability of patients to function independently, including being able to dress, feed themselves and participate in community activities. The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook.For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.MEDIA CONTACTSEisai Co., Ltd.Public Relations Department +81 (0)3-3817-5120Eisai Inc. (U.S.)Julie Edelman +1-862-213-5915 Julie_Edelman@eisai.com Eisai Europe, Ltd.EMEA Communications Department +44 (0) 797-487-9419 Emea-comms@eisai.net Biogen Inc.Jack Cox+ 1-781-464-3260 public.affairs@biogen.com Biogen Safe HarborThis news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty Copyright 2024 JCN Newswire via SeaPRwire.com.

Kawasaki, Japan and Santa Clara, California, Nov 1, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu and AMD (NASDAQ: AMD) today announced that they have signed a memorandum of understanding (MOU) to form a strategic partnership to create computing platforms for AI and high-performance computing (HPC). The partnership, encompassing all aspects from technology development to commercialization, will seek to facilitate the creation of open source and energy efficient platforms comprised of advanced processors with superior power performance and highly flexible AI/HPC software and aims to accelerate open-source AI and/or HPC initiatives.Due to the rapid spread of AI, including generative AI, cloud service providers and end-users are seeking optimized architectures at various price points and power per performance configurations. From end-to-end, AMD supports an open ecosystem, and strongly believes in giving customers choice. Fujitsu has worked to develop FUJITSU-MONAKA (1), a next-generation Arm-based processor that aims to achieve both high performance and low power consumption. With FUJITSU-MONAKA, together with AMD Instinct™ accelerators, customers have an additional choice to achieve large-scale AI workload processing to whilst attempting to reduce the data center total cost of ownership.This collaboration will focus on the three strategic areas of engineering, ecosystems, and business, bringing together Fujitsu’s world-leading supercomputer-based advanced CPU technology with industry-leading AMD GPU technology. Under this collaboration, Fujitsu and AMD will target joint development of innovative computing platforms for AI and HPC by 2027.In addition, based on AMD ROCm™ software, an open-source AI/HPC software stack for GPUs, and Fujitsu’s Arm-based FUJITSU-MONAKA software, Fujitsu and AMD will enhance their collaboration with the open-source community. Both companies seek to advance the development of open-source AI software that is optimized for the AI computing platforms they will provide, and work to expand the ecosystem.Fujitsu and AMD will also collaborate on marketing and co-creation with customers to offer these AI computing platforms globally. In addition, to expand AI use cases and promote the societal implementation of AI, based on the computing infrastructure of FUJITSU-MONAKA and AMD Instinct accelerators, both companies will collaborate to build an open and more sustainable AI/HPC platform ecosystem, including a joint customer center.Through this collaboration, Fujitsu and AMD are bringing their respective world-leading technologies together and will promote open-source AI initiatives by offering more sustainable options in both hardware and software that can be utilized by many companies.Vivek Mahajan, Corporate Vice President, CTO, CPO, Fujitsu Limited, comments:“Through this strategic partnership with AMD, Fujitsu seeks to accelerate open-source AI initiatives with a shared vision of achieving sustainable computing platforms. By combining AMD’s innovative GPU technology with Fujitsu’s low-power/high-performance processor FUJITSU-MONAKA, we seek to create an environment in which more companies will be able to utilize AI while reducing the power consumed by data centers. I believe that this partnership is an important step forward in accelerating Fujitsu’s efforts to achieve a sustainable society.”Phil Guido, EVP, Executive Vice President and Chief Commercial Officer, AMD comments:"By combining our cutting-edge AMD Instinct™ accelerators with Fujitsu’s advanced low-power processors, we are positioned to deliver high-performance and energy-efficient solutions that will benefit our joint AI and HPC customers. Our strategic partnership with Fujitsu not only underscores our commitment to innovation but also highlights our dedication to Japan, where we recognize the importance of local partnerships and expertise. As we continue to expand our relationships in Japan, we are excited about the opportunities to create a more sustainable computing infrastructure that aligns with Japan's technological leadership and commitment to sustainability."(1) FUJITSU-MONAKA :A processor based on the ARM instruction set architecture, employing cutting-edge 2-nanometer technology. It achieves high performance through utilizing Fujitsu’s proprietary many-core architecture for high performance and low power consumption. In addition, by supporting industry standard software through Fujitsu’s collaboration with the open-source community, FUJITSU-MONAKA promotes building an environment in which it is easy to maximize performance. This new technology applied to the FUJITSU-MONAKA is based on results obtained from a project subsidized by the New Energy and Industrial Technology Development Organization (NEDO).About AMDFor more than 50 years AMD has driven innovation in high-performance computing, graphics, and visualization technologies. Billions of people, leading Fortune 500 businesses, and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work, and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn and X pages.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesAMD PR agency, Burson JapanE-mail: AMDPR@bcw-global.com Copyright 2024 JCN Newswire via SeaPRwire.com.

HIROSHIMA, Japan, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation today launched a redesigned corporate website. Amid growing awareness and interest in sustainability, the company redesigned its website to provide stakeholders visiting the corporate website with more timely and user-friendly access to financial and non-financial data as well as information about initiatives set to enhance both corporate and social value.Within the corporate website, it also set up MAZDA MIRAI BASE, a new owned-media platform filled with videos and photos, to share stories about Mazda’s work to build a better future.Mazda Motor Corporation Website URL:Japanese - www.mazda.com/ja/English　-　www.mazda.com/en/MAZDA MIRAI BASE URL:Japanese　- www.mazda.com/ja/mazda-mirai-base/English - www.mazda.com/en/mazda-mirai-base/Key ImprovementsMazda’s website that presents the company’s worldview more clearly offering enhanced usabilityTo help our stakeholders quickly find information they need and access a broader range of corporate data, Mazda redesigned its website structure and reorganized the information posted. In addition, the content was optimized to convey Mazda’s corporate philosophy, established last year, and value creation approach, arranging these in a restructured corporate website that articulates our worldview seeking to create a vibrant future.New MAZDA MIRAI BASE platformThis new owned-media platform MAZDA MIRAI BASE has been created to share Mazda’s aspirations and initiatives for realizing its corporate philosophy and 2030 Vision. Working from the concept of a “media platform that connects with partners to create an exciting future,” MAZDA MIRAI BASE distributes articles, video and photos to tell stories about ”creating the joy of living” found in manufacturing safe and reliable automobiles, manufacturing sustainably, and creating moving experiences.Mazda will continue to pursue the ‘Joy of Driving’ under its core value “Human Centric,” and aim to deliver the ‘Joy of Living’ by creating moving experiences in customers' daily lives.Reference:Mazda’s Corporate Philosophy- Japanese　https://www.mazda.com/ja/about/philosophy/- English　　https://www.mazda.com/en/about/philosophy/ Copyright 2024 JCN Newswire via SeaPRwire.com.

Toyota City, Japan, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Today, Toyota Motor Corporation (hereafter, Toyota) and Nippon Telegraph and Telephone Corporation (hereafter, NTT) have agreed to a joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents.Through their previous collaborations, the two companies have confirmed that they share common values, such as contributing to society through technological and industrial development, a people-centered approach, and global contributions that start in Japan. This time, they will further deepen their collaboration with the aim of achieving a "society with zero traffic accidents" as the first step towards realizing a prosperous mobility society where safety and freedom are in harmony.In order to achieve a society with zero traffic accidents, it is necessary to take an infrastructure-cooperative approach that constantly connects people, mobility and infrastructure, in addition to the advancement of driving support technology based on data-driven technology in cars and the development of future automated driving technology.To achieve both of these things, Toyota is developing Software Defined Vehicles (SDV) with safety and security as the top priority. Alongside the evolution of SDV, it will become more important to build infrastructure such as a high-speed, high-quality communication infrastructure, an AI infrastructure that can collect and intelligently process vast amounts of information, and a computing infrastructure.In this collaboration, NTT, whose strengths lie in the telecommunications, and Toyota will jointly build a "Mobility AI Platform" that combines a seamless communications infrastructure with AI and computing platforms that can intelligently process large amounts of data. By doing so, they aim to connect people, mobility, and infrastructure to realize a safe, secure, and sustainable mobility society with no traffic accidents.Details of the joint initiativeWe will jointly develop and operate the "Mobility AI Platform" and use it in our efforts(1) to achieve a society with zero traffic accidents. The Mobility AI Platform is made up of multiple elements(2).The Mobility AI Platform aims to standardize the mobility field, and we envision that it will be used not only by the two companies, but also by a wide range of industry, government, and academic partners who share the goal of realizing a society with zero traffic accidents.Through this initiative, the two companies expect to invest a total of 500 billion yen by 2030. Starting in 2025, they will begin development of the Mobility AI Platform, and from around 2028 under the three-pronged infrastructure, they will begin social implementation and collaboration with various partners, aiming for widespread adoption from 2030 onwards.(1) Main initiatives aimed at achieving a society with zero traffic accidents- Three-pronged infrastructure collaboration" to prevent collisions at blind intersections, etc.- Development of advanced driving support/future automated driving systems" that are data-driven, with AI learning on its own based on large amounts of driving data(2) Elements that make up the mobility AI platform1. Distributed computing platform (data center)Computing resources (data centers) for analyzing and processing vast amounts of data using AI are installed in distributed locations, utilizing IOWN's optical communication technology. By locating them in areas rich in renewable energy, we can achieve local production for local consumption of electricity, and by achieving high power efficiency in the coordination and processing of distributed computing resources and AI, we can promote the greening of the vast amounts of electricity needed for data analysis and processing.2. Intelligent communication infrastructureA system is being built to coordinate human mobility infrastructure through seamless communication that is suitable for various traffic environments and conditions in urban areas, rural areas, and suburbs. In addition to being highly reliable, it also achieves low-latency communication for large volumes of data.3. AI infrastructureA platform that achieves mobility AI that learns and infers from various data from human mobility infrastructure, based on a "distributed computing infrastructure (data center)" and "intelligent communication infrastructure". Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that the all-new Triton has been selected as a golden award winner at the VMARK Vietnam Design Awards 2024 in the Best Transportation Design category. This marks the second time that Mitsubishi Motors has won the award, after the Xforce topped the same category in 2023.Established in 2018, the VMARK Vietnam Design Awards is organized by the VDAS Design Association based in Ho Chi Minh City. This year, a jury of 42 internationally renowned design practitioners evaluated design projects from Vietnam and around the world, and each entry was evaluated against the five criteria of innovativeness, eco-friendliness, identity, functionality, and community. The most outstanding designs received the golden award, and this year, 19 projects were selected as gold award winners out of a total of 700 entries.The Triton is Mitsubishi Motors' one-ton pickup truck that traces its roots back to the Forte originally released in 1978. In the 45 years since, this global strategic vehicle from Mitsubishi Motors has sold a cumulative total of approximately 5.7 million units in approximately 150 countries spanning five generations of models. Developed under the product concept of "Power for Adventure," the all-new Triton features a complete overhaul of everything from the interior and exterior design to the chassis, ladder frame and engine, and more. It was first launched in Thailand – where its production site is located – in July 2023 and introduced in Japan in February 2024. The all-new Triton is being rolled out sequentially in 100 countries worldwide.In attending the VMARK Vietnam Design Award 2024 ceremony, Kazuhiro Watanabe, Division General Manager of Sales & Marketing Division, Mitsubishi Motors Vietnam Co., Ltd., commented: “This award is a testament to our 30-year journey of 'Drive ahead together for everyday Adventure' in Vietnam. The all-new Triton embodies this commitment by delivering exceptional quality, innovation, and a driving experience that resonates with the adventurous spirit of the Vietnamese people.”Norihiko Yoshimine, Product Design Director, Mitsubishi Motors, who designed the Triton, cheerfully commented, “The Triton expresses the majestic aura that is distinctively Mitsubishi, possessing both robustness and agility in addition to the toughness and sheer power expected of a pickup truck. Following in the footsteps of the award for the Xforce last year, I am deeply honored that the all-new Triton has earned such high recognition at the VMARK Vietnam Design Awards this year. This award will provide a boost, but we will also continue doing our utmost to promote the Triton’s appeal to even more customers in Vietnam.”VMARK Vietnam Design Awards 2024 Awards Page (only available in English and Vietnamese) https://www.vietnamdesignweek.org/vmark-vietnam-design-week-2024About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society.For more information on Mitsubishi Motors, please visit the company's website athttps://www.mitsubishi-motors.com/en/ Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc.  announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Clinical Trials for Alzheimer's Disease Conference (CTAD), held in Madrid, Spain, and virtually.Benefits of Continued Treatment with Lecanemab for People with Early ADIn July 2024 at the Alzheimer's Association International Conference (AAIC) 2024, results from the open-label long-term extension study (OLE) following the core study of the lecanemab Phase 3 Clarity AD study were presented, showing that the mean change from baseline in CDR-SB (global cognitive and functional scale) in the lecanemab treated group relative to the placebo group was -0.45 at 18 months, and at 36 months, this expanded to -0.95 compared to a prespecified natural history** cohort of AD. There was a 30% reduction in the relative risk of progressing to the next disease stage In addition, the tau PET substudy of the lecanemab Phase 3 Clarity AD clinical study showed that with three (3) years of continuous treatment with lecanemab, 59% of patients with no or low tau accumulation in the brain (no tau/low tau) at baseline showed improvement or no decline, and 51% showed improvement from baseline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) global cognitive and functional scale.1Clarity AD data presented at CTAD expand on these initial results to include additional measurements resulting from three (3) years of continuous lecanemab treatment in patients with low levels of amyloid accumulation in the brain at baseline (less than 60 Centiloids: low amyloid). These data show that 46% of patients improved or had no decline, and 33% showed improvement from baseline on the CDR-SB. On the ADAS-Cog14 measurement scale, 46% of patients showed improvement or no decline and 43% showed improvement. On the ADCS MCI-ADL, 51% of patients showed improvement or no decline and 48% showed improvement. These results – from no tau/low tau population and low amyloid populations – suggest that earlier initiation of lecanemab treatment may have a positive impact on disease progression of early AD patients and may provide continued benefits to patients with early AD over the long term.2No new safety findings were observed with continued lecanemab treatment over three (3) years. Most amyloid-related imaging abnormalities (ARIA) occurred in the first six (6) months of treatment. After the first six (6) months, ARIA rates were low and similar to ARIA rates on placebo during the placebo- controlled period. With regards to the incidence of ARIA by ApoEε4 status during the continuous treatment, the incidence was higher in ApoE4 homozygotes than in heterozygotes or non-carriers, but rates of new ARIA were decreased after the completion of the 18 months core study as treatment continued, regardless of ApoEε4 status.2Correlation between Protofibrils and Biomarkers for Neurodegenerative Disease in the AD Brain Dual-acting lecanemab is the only early AD treatment available to support neuronal function by clearing the highly toxic protofibrils that continue to cause neuronal injury and death even after plaques have been cleared from the brain. Protofibrils accumulate early in the AD brain and lead to nerve cell function loss, abnormal nerve processes, inflammation, and memory loss. In non-clinical studies, antibodies against protofibrils prevented protofibril-mediated neuronal dysfunction and memory loss.Accurately quantifying the amount of protofibrils in human cerebrospinal fluid (CSF) has been challenging due to their low concentration. As such, a new measurement method was developed by researchers at Eisai to accurately quantify protofibrils in CSF.Utilizing this new method of measurement, the amount of protofibrils in AD CSF correlated more strongly with neurodegenerative disease biomarkers (CSF total tau and neurogranin) than with CSF Aβ42, a biomarker associated with Aβ plaques accumulation, indicating that protofibrils are closely related to synaptic dysfunction. Furthermore, it was observed that protofibrils, unlike plaques, are diffusible. These results suggest that protofibrils induce synaptic dysfunction, playing an important role in neurodegeneration in AD brains.3Lecanemab Treatment for Early AD: Insights from Long-Term U.S. Clinical StudiesDr. Marwan Noel Sabbagh, Moreno Family Chair for Alzheimer's Research and Vice Chairman for Research and Professor, Department of Neurology, Barrow Neurological Institute, presented outcomes of an analysis of the use of lecanemab treatment between January 6, 2023, and July 30, 2024, based on payment claims data from the Komodo Research Database, a medical database in the U.S. In the U.S., lecanemab is used in accordance with the US FDA-approved indication, dosing, and monitoring guidelines. The analysis found that access to lecanemab treatment is expanding and highlighted opportunities to improve access in rural areas and educational outreach for underserved populations.4Dr. David Watson of the Alzheimer's Research and Treatment Center reported on patients who continued to receive lecanemab treatment following the Phase II Study 201 and Phase III Clarity AD study. A total of 136 patients participated in both studies at this center, and 66 patients chose to continue lecanemab therapy, with 13 patients receiving treatment for more than five (5) years and 40 patients receiving treatment for more than three (3) years. More than half of the patients (15/24) who continued treatment with lecanemab for more than three (3) years after the core phase remained in their initial stage of disease. Further, in a survey of 11 patients (or their caregivers) who received lecanemab treatment for more than five (5) years, all patients responded that they were “very satisfied” or “satisfied” with lecanemab treatment. In addition, between 45% and 73% of patients responded that lecanemab treatment made them feel more positive about their daily life, social activities, memory, etc. "frequently" or "very often."5No new long-term safety findings were observed in these multi-year studies.5Progress in the AHEAD 3-45 Study: Improving Screening Eligibility Using Blood Biomarkers and Completing Patient EnrollmentAHEAD 3-45 is a Phase 3 clinical study for individuals with preclinical AD, meaning they are clinically unimpaired but have intermediate or elevated levels of amyloid in their brains. In the study, blood tests, cognitive function tests (PACC-5***), amyloid PET, MRI, and tau PET were used for screening. Based on the amount of Aβ accumulation in the brain as determined by amyloid PET, subjects were assigned to two (2) trials with different dose settings: the A3 trial, for those with borderline Aβ levels in the brain, and the A45 trial, for those with positive Aβ levels in the brain.6Screening with blood biomarker tests was important to improve eligibility for amyloid PET testing in subjects without cognitive impairment. Using plasma Aβ42/40 ratio and p-tau217/tau217 ratio in theinitial screening reduced screening failure on amyloid PET from more than 70% to less than 30%. In particular, plasma p-tau217 was shown to correlate with amyloid PET, supporting its role as a useful blood biomarker to identify elevated amyloid in the brain.6Enrollment for the AHEAD 3-45 study was completed in October 2024.Lifetime Achievement Award Presented to Professor LannfeltProfessor Emeritus Lars Lannfelt of Uppsala University received the CTAD Lifetime Achievement Award in recognition of his pioneering work in scientific discovery and drug development in AD. As part of this award ceremony, he delivered a keynote speech outlining the discovery of the arctic mutation in familial AD, its application to therapeutic strategies targeting protofibrils for AD treatment, and the development of lecanemab.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision- making authority.*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline of this progressive, debilitating condition.7 Protofibrils cause injury to neurons in the brain which, in turn, can negatively impact cognitive function through multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.8**ADNI is a clinical research project launched in 2005 to develop methods to predict the onset of AD and to confirm the effectiveness of treatments. The ADNI observational cohort was pre-specified and used during the design of Clarity AD. The cohort represents the exact population of those in Clarity AD study; matched ADNI participants show similar degree of decline to placebo group out to 18 months.***PACC-5 is a composite measure that provides a highly sensitive measure of changes in cognitive function in individuals with preclinical AD.About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates and Great Britain. Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union (EU).LEQEMBI’s approvals in these countries were based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with lecanemab reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.9,10 The mean CDR- SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001). In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the lecanemab group and −5.5 in the placebo group (difference, 2.0; 95% CI, 1.2 to 2.8; P<0.001). The ADCS MCI-ADL assesses the ability of patients to function independently, including being able to dress, feed themselves and participate in community activities. The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.In July 2024 Eisai presented 36-month data from the Phase 3 Clarity AD Open-Label Extension Study demonstrating that LEQEMBI-treated patients continued to show benefit at 36 months of treatment. In the 18-month core study of Clarity AD, there was a statistically significant difference in global cognition and function as measured by CDR-SB between the LEQEMBI and placebo groups. The separation in CDR-SB between the group that continued to receive LEQEMBI (early start group) and the group who switched from placebo to LEQEMBI (delayed start group) was maintained during the 6-month OLE following the core study. This indicates that similar disease trajectory for both early and delayed start groups occurred with LEQEMBI administration. The blood biomarker results (plasma Aβ42/40 ratio, ptau181, GFAP and NfL) showed improvement even after delayed initiation of treatment with LEQEMBI.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti- amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.References:(1) Sperling, R., Selkoe, D., Reyderman, L., Youfang, C., Van Dyck, C. (2024, July 28 - August 1). Does the Current Evidence Base Support Lecanemab Continued Dosing for Early Alzheimer's Disease? [Perspectives Session] Alzheimer's Association International Conference, Philadelphia, PA, United States.(2) Van Dyck, C. (2024, October 29-November 1). Does the Current Evidence Base Support Lecanemab Continued Dosing for Early Alzheimer's Disease? [Symposium on Lecanemab Continued Dosing] Clinical Trials for Alzheimer's Disease, Madrid, Spain.(3) De Simone, F., Buitrago, L., Benina, N., et al. (2024, October 29-November 1). The use of plasma biomarkers for the prediction of Amyloid positivity. [Oral Presentation] Clinical Trials for Alzheimer’s Disease, Madrid, Spain.(4) Sabbagh, M., Zhao, C., Mahendran, M. et al. (2024, October 29-November 1). Lecanemab Treatment in Real World Settings in the United States. [Late Breaking Symposium 2]. Clinical Trials for Alzheimer's Disease, Madrid, Spain.(5) Watson, D., Neam, M., Stafford, M. et al. (2024, October 29-November 1). Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease Treatment Center. [Poster Presentation]. Clinical Trials for Alzheimer's Disease, Madrid, Spain.(6) Sperling, RA., Rissman, R., Johnson, KA., et al. (2024, October 29-November 1). Screening Plasma Biomarkers, Amyloid and Tau PET Imaging in the AHEAD 3-5 Study. [Late Breaking Symposium 1]. Clinical Trials for Alzheimer's Disease, Madrid, Spain.(7) Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z(8) Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.(9) Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at: www.eisai.com/news/2022/news202285.html(10) van Dyck, C., et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023;388:9-21. www.nejm.org/doi/full/10.1056/NEJMoa2212948.MEDIA CONTACTSEisai Co., Ltd.Public Relations Department+81-(0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797-487-9419Emea-comms@eisai.netBiogen Inc. Jack Cox+ 1-781-464-3260public.affairs@biogen.comEisai Inc. (U.S.) Julie Edelman+1-862-213-5915Julie_Edelman@eisai.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations Department+81-(0) 3-3817-5122Biogen Inc. Stephen Amato+1-781-464-2442IR@biogen.comBiogen Safe HarborThis news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates; including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of the medicine; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements. Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) -  Eisai Co. Ltd announced today that the latest findings on anti-MTBR (microtubule binding region) tau antibody E2814 were presented at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in Madrid, Spain, and virtually. Eisai also announced initiation of a Phase II study (Study 202) on E2814 for sporadic early Alzheimer’s Disease (AD).Impact of the anti-MTBR tau antibody E2814 on tau pathology biomarkers in Dominantly Inherited Alzheimer’s Disease (DIAD)E2814 is an investigational anti-MTBR tau antibody designed to target the MTBR of tau. In AD patients, neurofibrillary tangles (NFT) are a pathological hallmark, and they are believed to spread through synaptically connected pathways in the brain, forming the tau propagation hypothesis. It is thought that tau propagation is drivenby the specific tau species containing MTBR, tau seeds that spread tau pathology to different brain regions important for cognition and function.Eisai conducted a Phase I/II clinical study (Study 103, NCT04971733; 7 participants) of the anti-MTBR tau antibody E2814 in patients with Dominantly Inherited Alzheimer’s Disease (DIAD) beginning in June 2021. This study aimed to evaluate the safety and tolerability of E2814 in DIAD patients, with a primary objective of assessing the target engagement of E2814 with MTBR-tau species in their cerebrospinal fluid (CSF). In addition, pharmacodynamicevaluation was performed using multiple biomarkers related to AD tau pathology. In the study, DIAD patients withclinical symptoms were administered E2814 for 12 to 24 months. Data from the Dominantly Inherited Alzheimer Network Observational Study (DIAN-obs), an observational cohort of DIAD, were used as references to evaluate biomarkers changes in E2814 treatment.Compared to the reference data from DIAN-obs, patients who received E2814 showed approximately 75% and 50% reductions of CSF MTBR-tau243 and p-tau217, respectively, reflecting tau pathophysiology. Additionally, braintau accumulation observed by tau PET was stabilized or trended toward decrease in DIAD subjects administered E2814. These results suggest that E2814 inhibited tau propagation and suppressed the accumulation of tau aggregates in brains of people living with DIAD. This will be further investigated in the ongoing Phase II/III Tau NexGen study (NCT05269394) with DIAD patients and the Phase II 202 study (NCT06602258) with sporadic early Alzheimer’s disease (AD) patients.Initiation of Phase II clinical study (Study 202)In September 2024, Eisai initiated a Phase II clinical study (Study 202) for individuals with early AD in the United States. The study is also scheduled to be conducted in Japan in the future. This study is a placebo- controlled,double-blind, parallel-group, dose exploration study, evaluating the safety, tolerability, and biomarker efficacy of E2814 in people living with early AD receiving lecanemab as a backbone anti-Aβ therapy.Eisai positions neurology as a key therapeutic area, and it will continue to create innovation in the development of novel medicines based on cutting-edge neurology research as it seeks to contribute further to improving the benefits of affected individuals and their families in diseases with high unmet needs, such as dementia including AD.This release discusses investigational uses of agents in development and is not intended to convey conclusionsabout efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.About E2814An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease- modifying agent for tauopathies including sporadic Alzheimer’s disease (AD). Phase I clinical studies are underway. E2814 was discovered as part of the research collaboration between Eisai and University College London. E2814 is designed to prevent the spreading of tau seeds within the brains of affected individuals. In addition, E2814 has been selected as an anti-tautherapy in a Phase II/III Tau NexGen study for the treatment of DIAD, conducted by DIAN-TU led by Washington University School of Medicine in St. Louis, is underway.Biomarkers related to AD tau pathologyAs fluid biomarkers related to AD tau pathology, tau containing the residue 243 (MTBR-tau243) and tau phosphorylated at theresidue 217 (p-tau217) in CSF have been reported.1 In addition, positron emission tomography (tau PET), which specifically detects tau aggregates, is used as an imaging biomarker. These biomarkers are included in the Revised criteria for diagnosis and staging of Alzheimer's disease published by the National Institute on Aging and the Alzheimer's Association (NIA-AA) in June 2024.2(1) Horie K, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. Nat Med. 2023. 29. 1954-1963(2) Jack Jr. CR, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024. 20. 5143-5169For further information: Media Inquiries:Eisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Eisai Inc. (U.S.) Libby Holman+1-201-753-1945Libby_Holman@Eisai.comEisai Europe, Ltd. (UK, Europe, Australia, New Zealand and Russia) EMEA Communications Department+44 (0) 786 601 1272EMEA-comms@eisai.net Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Oct 30, 2024 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation's production and sales results for September 2024 and for April through September 2024 are summarized below.I. Production BreakdownSeptember 2024Apr - Sep 2024Jan - Sep 2024UnitsYoYChange (%)UnitsYoYChange (%)UnitsYoYChange (%)DOMESTIC PRODUCTIONPassenger Vehicles65,047-18.8375,643-5.9558,969-10.2Total65,047-18.8375,643-5.9558,969-10.2 OVERSEAS PRODUCTIONPassenger Vehicles39,244+0.4226,952+17.1335,277+13.1Total39,244+0.4226,952+17.1335,277+13.1 GLOBAL PRODUCTIONPassenger Vehicles104,291-12.5602,595+1.6894,246-2.7Total104,291-12.5602,595+1.6894,246-2.71. Domestic Production(1) September 2024Mazda's domestic production volume in September 2024 decreased 18.8% year on year due to decreased production of passenger vehicles.[Domestic production of key models in September 2024]CX-5:21,133 units(down 40.8% year on year)MAZDA3:10,704 units(up 25.0%)CX-90:7,296 units(down 14.9%)(2) April through September 2024Mazda's domestic production volume in the period from April through September 2024 decreased 5.9% year on year due to decreased production of passenger vehicles.[Domestic production of key models in the period from April through September 2024]CX-5:141,007 units(down 19.8% year on year)MAZDA3:53,009 units(up 6.7%)CX-90:50,331 units(up 42.0%)2. Overseas Production(1) September 2024Mazda's overseas production volume in September 2024 increased 0.4% year on year due to increased production of passenger vehicles.[Overseas production of key models in September 2024]CX-30:11,527 units(down 2.6% year on year)CX-50:9,985 units(up 21.9%)MAZDA3:5,276 units(down 55.5%)(2) April through September 2024Mazda's overseas production volume in the period from April through September 2024 increased 17.1% year on year due to increased production of passenger vehicles.[Overseas production of key models in the period from April through September 2024]CX-30:64,436 units(up 0.2% year on year)CX-50:58,866 units(up 50.1%)MAZDA3:32,646 units(down 21.8%)II. Domestic Sales BreakdownSeptember 2024Apr - Sep 2024Jan - Sep 2024UnitsYoYChange (%)UnitsYoYChange (%)UnitsYoYChange (%)DOMESTIC SALESPassenger Vehicles12,617+14.059,304-21.995,947-26.1Commercial Vehicles923-7.34,850-17.97,674-17.4 Registration Total9,973+14.546,586-27.074,689-33.0Micro-mini Total3,567+6.517,568-2.828,932+4.9Total13,540+12.364,154-21.6103,621-25.5(1) September 2024Mazda's domestic sales volume in September 2024 increased 12.3% year on year due to increased sales of passenger vehicles.Mazda's registered vehicle market share was 3.6% (up 0.4 points year on year), with a 2.2% share of the micro-mini segment (up 0.2 points) and a 3.1% total market share (up 0.3 points).[Domestic sales of key models in September 2024]MAZDA2:2,354 units(up 53.3% year on year)CX-5:2,252 units(up 51.1%)CX-30:1,467 units(up 264.9%)(2) April through September 2024Mazda's domestic sales volume in the period from April through September 2024 decreased 21.6% year on year due to decreased sales of passenger and commercial vehicles.Mazda's registered vehicle market share was 3.3% (down 1.2 points year on year), with a 2.3% share of the micro-mini segment (unchanged year on year) and a 3.0% total market share (down 0.7 points).[Domestic sales of key models in the period from April through September 2024]MAZDA2:12,031 units(up 22.8% year on year)CX-5:9,619 units(down 21.4%)CX-30:6,702 units(down 4.3%)III. Exports BreakdownSeptember 2024Apr - Sep 2024Jan - Sep 2024UnitsYoYChange (%)UnitsYoYChange (%)UnitsYoYChange (%)EXPORTSPassenger Vehicles54,988-15.4334,553-2.1487,949-6.5 North America21,985-6.9151,152+13.0210,401+0.1Europe9,926-38.758,950-36.5107,451-19.2Oceania6,296-3.234,462-3.947,417-7.5Others16,781-10.489,989+13.8122,680-3.9Total54,988-15.4334,553-2.1487,949-6.5(1) September 2024Mazda's export volume in September 2024 decreased 15.4% year on year due to decreased shipments to Europe, North America, Oceania, and other regions.[Exports of key models in September 2024]CX-5:19,047 units(down 38.0% year on year)MAZDA3:9,720 units(up 48.1%)CX-90:8,306 units(up 13.1%)(2) April through September 2024Mazda's export volume in the period from April through September 2024 decreased 2.1% year on year due to decreased shipments to Europe, and Oceania.[Exports of key models in the period from April through September 2024]CX-5:135,974 units(down 16.7% year on year)CX-90:50,103 units(up 45.8%)MAZDA3:49,165 units(up 13.8%)IV. Global Sales BreakdownSeptember 2024Apr - Sep 2024Jan - Sep 2024UnitsYoY Change (%)UnitsYoY Change (%)UnitsYoY Change (%)GLOBAL SALESDomestic Sales13,540+12.364,154-21.6103,621-25.5 U.S.A29,840+6.5213,345+15.8313,449+15.0 China6,425-33.134,424-23.958,139+1.5 Europe17,158-15.288,591-1.3134,540-5.2 Others40,324+8.6229,513+6.6331,359+3.4Overseas Sales93,747-1.3565,873+5.8837,487+5.7Total107,287+0.2630,027+2.2941,108+1.0(1) September 2024Mazda's global sales volume in September 2024 increased 0.2% year on year due to increased sales in the U.S., Japan, and other regions.[Global sales of key models in September 2024]CX-5:29,373 units(up 7.2% year on year)CX-30:18,362 units(down 2.1%)MAZDA3:12,395 units(down 34.1%)(2) April through September 2024Mazda's global sales volume in the period from April through September 2024 increased 2.2% year on year due to increased sales in the U.S., and other regions.[Global sales of key models in the period from April through September 2024]CX-5:176,597 units(up 1.3% year on year)CX-30:113,133 units(up 13.3%)MAZDA3:80,824 units(down 9.7%)(1) Overseas production figures indicate Mazda-brand units coming off the production line (excluding CKD units).(2) Global production figures are the sum total of domestic and overseas production volumes.(3) All information in this press release is as of the date of the publicity. No updates after that date are reflected. Copyright 2024 JCN Newswire via SeaPRwire.com.

Toyota City, Japan, Oct 30, 2024 - (JCN Newswire via SeaPRwire.com) - Suzuki Motor Corporation (Suzuki) and Toyota Motor Corporation (Toyota) have decided to further strengthen collaboration in the supply of a battery EV (BEV) SUV model developed by Suzuki to Toyota. This new model is scheduled to be manufactured at Suzuki Motor Gujarat in India from the spring of 2025.Both Suzuki and Toyota's businesses have their roots in Enshu―the western part of Shizuoka Prefecture―and both companies took on the challenge of switching their businesses from looms to automobiles. Since Suzuki's Chairman (current Senior Advisor) Osamu Suzuki and Toyota's President (current Chairman) Akio Toyoda started exploring business partnerships in 2016, both companies have engaged in a wide-ranging collaboration, aiming to provide people with freedom of movement and fun-to-drive. The fields of collaboration are diverse and include production and mutual supply of vehicles, and the spread of electrified vehicles. As a result, the market launch of collaboration vehicles has expanded to Japan, India, Europe, Africa, and the Middle East.This new development marks the first BEV in the OEM relationship between the two companies. It will be launched worldwide, providing a BEV choice even in the SUV market, which is showing remarkable growth. With this new addition, Suzuki and Toyota will further promote their respective initiatives toward realizing a carbon-neutral society.The new model was designed exclusively as a BEV. A nimble SUV with the sharp driving characteristics of a BEV, it features ample cruising range and a comfortable cabin. It is also available with a 4WD system, offering exceptional drivability on rough roads and a more powerful driving performance.The BEV unit and platform adopted for this model were jointly developed by Suzuki, Toyota, and Daihatsu Motor Co., Ltd., utilizing each company's strength.Comment from Suzuki President Toshihiro Suzuki"Suzuki will supply our first BEV to Toyota globally. I am grateful that the collaboration between the two companies has further deepened in this way. While continuing to be competitors, we will deepen our collaborations toward solving social issues, including the realization of a carbon-neutral society through a multi-pathway approach."Comment from Toyota President Koji Sato"By leveraging the BEV unit and platform that we jointly developed, we will take a new step in our collaboration in the field of electrified vehicles. This will allow us to deliver various choices that contribute to a carbon-neutral society to customers worldwide. We would like to learn from each other's strengths, compete, and further joint efforts based on a multi-pathway approach."About Toyota Motor CorporationToyota Motor Corporation works to develop and manufacture innovative, safe and high-quality products and services that create happiness by providing mobility for all. We believe that true achievement comes from supporting our customers, partners, employees, and the communities in which we operate. Since our founding over 80 years ago in 1937, we have applied our Guiding Principles in pursuit of a safer, greener and more inclusive society. Today, as we transform into a mobility company developing connected, automated, shared and electrified technologies, we also remain true to our Guiding Principles and many of the United Nations' Sustainable Development Goals to help realize an ever-better world, where everyone is free to move.SDGs Initiatives: https://global.toyota/en/sustainability/sdgs/ Copyright 2024 JCN Newswire via SeaPRwire.com.

KAWASAKI, Japan, Oct 30, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu and Morinaga Milk Industry Co., Ltd. have jointly developed a system that simulates the impact of raw material price and exchange rate fluctuations on management initiatives and business profits. This system utilizes the Fujitsu Manufacturing Supply Chain Planning offering (1) and is currently in use by Morinaga Milk Industry.Morinaga Milk Industry previously carried out manual data collection among its 23 domestic factories and hundreds of suppliers. This system streamlines the process, enabling early visualization of the impact of raw material price fluctuations, thus contributing to faster decision-making. A two-month trial run with Morinaga Milk Industry carried out previously confirmed improvements in work efficiency and standardization.Fujitsu will continue to support Morinaga Milk Industry's efforts to foster a corporate culture of taking on challenges and contribute to the healthy and happy lives of its customers, viewing this transformation as the essence of Digital Transformation (DX) promotion.OverviewFujitsu Manufacturing Supply Chain Planning is an advanced planning and simulation platform that leverages Fujitsu's deep understanding of industry-specific processes, data, algorithms, business practices, and system architecture cultivated over 30 years.The system provided to Morinaga Milk Industry significantly reduces the time required to grasp and analyze the impact of raw material price fluctuations on profits, enhancing responsiveness to change. Its diverse simulation capabilities will support a shift toward advanced operations, i.e., sales and procurement planning that is adaptable to future expansion, and contribute to cost optimization.Figure 1: Diagram of system provided to Morinaga Milk IndustryFuture PlansWith the launch of integrated budget-sales-supply and demand planning templates on October 1, 2024, Fujitsu plans to expand its offerings to manufacturers who want to be able to respond rapidly to demand fluctuations and inventory optimization.[1]Fujitsu Manufacturing Supply Chain Planning :An offering that realizes a robust and efficient supply chain by supporting rapid decision-making from management to the field and throughout the supply chain through integrated planning that considers supply chain risks. It combines Fujitsu's in-house developed manufacturing scheduler and risk management with Fujitsu's unique templates built on the "Anaplan" platform, the scenario planning and analysis platform designed to optimize decision-making.Fujitsu’s Commitment to the Sustainable Development Goals (SDGs)The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030.Fujitsu’s purpose — “to make the world more sustainable by building trust in society through innovation” — is a promise to contribute to the vision of a better future empowered by the SDGs.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Oct 30, 2024 - (JCN Newswire via SeaPRwire.com) - NTT DOCOMO, INC. announced today that it will exhibit an ultra-modern virtual city called “Future Youth City” in the Virtual Expo—Yumeshima Islands in the Sky, the virtual site of Expo 2025 Osaka, Kansai, Japan (“the Expo”), which is planned to be held in Osaka, Japan for six months from April 2025.Future Youth City presents model futuristic city, based on the concept of “Mirai no machi” (City of the future), which represents a collective vision for the future, demonstrating what it might look like when everyone's dreams become reality. It showcases a future with enhanced and innovative communication methods, by combining ideas of forward-thinking students and DOCOMO's cutting-edge technology, FEEL TECH®,*1 This innovation utilizes Human Augmentation Platform® to share human motions and senses as information personalized for the receiver.The virtual space will feature 3 areas. Mirai (future) Street, the main street of Future Youth City lined with futuristic entertainment and dining experiences, and Mirai House, a co-living space that will use advanced technology to meet diverse residential needs. Both will showcase a world where people can enjoy the new way of communication, shaped by dreams and ideas, on the metaverse supported by FEEL TECH.Visitors to the virtual space will be able to observe non-player character (NPC) residents of the metaverse experiencing the future as they interact with each other, including through realistic conversations. Additionally, the “docomo Technology Lab” (tentative name) on Mirai Street plans to showcase DOCOMO's latest achievements in sensory sharing with FEEL TECH.The virtual space will also feature Future Gallery, which will exhibit children's artistic depictions of a prosperous future based on the theme of “Our Future Lives.” The exhibits will feature a variety of children's creations that envision different futures, including award-winning pieces with a special connection to the Expo, presented by the docomo Future Museum,*2 which has been hosting children's art competitions since 2002 and now in its 23rdyear.By participating in the Expo, DOCOMO aims to bring the “Mirai no machi” concept to life, transforming futuristic ideas and dreams into reality.What is Virtual Expo Yumeshima Islands in the Sky?Virtual Expo —Yumeshima Islands in the Sky is the virtual site of Expo 2025 Osaka, Kansai, Japan. Visitors can immerse themselves in the world of the Expo as avatars, navigating pavilions and event facilities that are reproductions of actual buildings, while enjoying unique exhibitions and events developed by each exhibitor–experiences that are only possible in the virtual world. Look forward to a six-month journey where you will travel with people from all over the world and explore a future society for our lives. Additionally, the Japan Association for the 2025 World Exposition will provide a downloadable Virtual Expo app. For compatible devices and detailed instructions, please visit the Japan Association for the 2025 World Exposition website at www.expo2025.or.jp/en/future-index/virtual/virtual-site/Nippon Telegraph and Telephone Corporation, DOCOMO's parent company, is a sponsor of the Virtual Expo as part of the Future Society Showcase project.https://group.ntt/en/expo2025/NTT DOCOMO Group Expo 2025 Osaka, Kansai, Japan Websitehttps://www.docomo.ne.jp/english/corporate/about/expo2025/(1) FEEL TECH is one of DOCOMO's technologies for the 6G era, that utilizes Human Augmentation Platform to share human motions and senses as information personalized for the receiver. (2) https://docomo-mirai.tda.docomo.ne.jp/museum/ (Only available in Japanese)FEEL TECH and Human Augmentation Platform are registered trademarks of NTT DOCOMO in Japan.About NTT DOCOMONTT DOCOMO, Japan's leading mobile operator with over 89 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.https://www.docomo.ne.jp/english/ Copyright 2024 JCN Newswire via SeaPRwire.com.

CHIGASAKI, JP / PYEONGTAEK, KR, Oct 30, 2024 - (JCN Newswire via SeaPRwire.com) - ULVAC, Inc., the world’s leading comprehensive vacuum manufacturer, has established Technology Center PYEONGTAEK in Pyeongtaek, Gyeonggi-do, South Korea.The Center aims to advance the development of next-generation semiconductor manufacturing equipment and processes in collaboration with customers in South Korea, while also establishing mass production technologies. The Center commenced operations in August 2024[1] and held an opening ceremony on October 24.As the technical complexity in semiconductor manufacturing equipment is rapidly increasing, close joint development with leading semiconductor manufacturers is essential to provide competitive products to the market. Technology Center PYEONGTAEK will leverage the ULVAC Group’s extensive human resources and expertise to promptly deliver high-quality manufacturing equipment that meets customer needs while also enhancing technical support.ULVAC positions the Center as a 'Field of Potentiality'[2] for the future by fostering innovation. By promoting co-creation with customers, we strive to fulfil our corporate mission of 'contributing to the advancement of industry and science through the comprehensive utilization of vacuum technology and its surrounding technologies.'Opening CeremonyThe opening ceremony, held on October 24, was attended by partner companies, Gyeonggi-do officials, and ULVAC representatives. President & CEO Setsuo Iwashita expressed his gratitude for the efforts of all involved and stated, "We aim to respond swiftly and accurately to our customers' needs and grow together."President & CEO of ULVAC, Setsuo Iwashita, giving a speech at the opening ceremony.In his congratulatory speech, 1st Vice Governor for Administrative Affairs of Gyeonggi-do, Kim Seong-joong, remarked, "The establishment of this Center was made possible thanks to the long-standing trust and cooperation between Gyeonggi-do and ULVAC. I hope that many talented individuals will come together here to create world-leading technologies. Gyeonggi-do will continue to provide full administrative support to offer a platform for outstanding talent to realize their dreams."[1] February 13, 2023 News Release: "ULVAC Announces a Construction of Technology Center PYEONGTAEK"https://ir.ulvac.co.jp/en/ir/newsrelease/auto_20230213508142/pdfFile.pdf  [2] "Field of Potentiality" for the futureThe ULVAC Group has established the ideal vision for 2032, "Vision 2032," to continue being a "Field of Potentiality" for the future. The concept of "Field of Potentiality" is inspired by the physical phenomenon that occurs in a vacuum, where energy is injected into a vacuum, something new is created. The ULVAC Group is committed to advancing its core vacuum technology while understanding the needs of its customers and addressing social challenges, thereby continuously creating truly valuable technologies and products.About ULVAC, Inc. Since its founding in 1952, ULVAC, Inc. has been a comprehensive vacuum equipment manufacturer, providing manufacturing equipment, components, analytical instruments, materials, and services based on its core technology—vacuum technology. Working with customers across a wide range of industries, including semiconductors, electronic components, displays, automotive, and pharmaceuticals, ULVAC is committed to driving cutting-edge innovation and creating new value. For the fiscal year ending June 2024, the ULVAC Group recorded consolidated sales of 261.1 billion yen and has approximately 6,200 employees.For more information, please visit our official website at https://www.ulvac.co.jp/en/.For more information:ULVAC, Inc.https://www.ulvac.co.jp/en/contact/general.html  Copyright 2024 JCN Newswire via SeaPRwire.com.